Clinical characteristics of and growth hormone treatment effects on short stature with type 1 insulin-like growth factor receptor (IGF1R) gene alteration
Endocrine Journal · 2024
DOI: 10.1507/endocrj.ej23-0680 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Journal, 2024. Verfasst von Yuki Kawashima-Sonoyama und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Shimane University Faculty of Medicine, Shimane 693-8501, Japan. Hauptthemen laut MEDLINE: Receptor, IGF Type 1, Human Growth Hormone, Growth Disorders, Infant, Small for Gestational Age. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Shimane University Faculty of Medicine, Shimane 693-8501, Japan.
- Division of Pediatrics & Perinatology, Tottori University Faculty of Medicine, Tottori 683-8504, Japan.
Zitieren
APA
Kawashima-Sonoyama, Y., Wada, K., Yamamoto, K., Fujimoto, M., Namba, N., & Taketani, T. (2024). Clinical characteristics of and growth hormone treatment effects on short stature with type 1 insulin-like growth factor receptor (IGF1R) gene alteration. Endocrine Journal. https://doi.org/10.1507/endocrj.ej23-0680
Vancouver
Kawashima-Sonoyama Y, Wada K, Yamamoto K, Fujimoto M, Namba N, Taketani T. Clinical characteristics of and growth hormone treatment effects on short stature with type 1 insulin-like growth factor receptor (IGF1R) gene alteration. Endocrine Journal. 2024. doi:10.1507/endocrj.ej23-0680
BibTeX
@article{KawashimaSonoyama2024,
author = {Kawashima-Sonoyama, Yuki and Wada, Keisuke and Yamamoto, Kei and Fujimoto, Masanobu and Namba, Noriyuki and Taketani, Takeshi},
title = {Clinical characteristics of and growth hormone treatment effects on short stature with type 1 insulin-like growth factor receptor (IGF1R) gene alteration},
journal = {Endocrine Journal},
year = {2024},
doi = {10.1507/endocrj.ej23-0680}
}
EUVIMED